Beth Altman, former Managing Partner at KPMG LLP San Diego, has been appointed as an independent director to the Alphatec Holdings, Inc. (ATEC) Board of Directors and as chair of the Board’s Audit Committee. Donald A. Williams has resigned as an independent director and as Chair of the Audit Committee of the Board and member of its Finance Committee.
Beth Altman Joins Alphatec Spine’s Board of Directors
Altman, an audit partner with KPMG US for over 26 years, is also the former Managing Partner of the firm’s 300-person San Diego office. Her breadth of experience encompasses life science, consumer markets and technology sector expertise; she has also served as lead partner for many multinational public clients. She sits on the board of Allscripts and CV Sciences and “…was previously on the board of the Corporate Directors Forum, a 501(c)(6) nonprofit organization focused on helping Directors build more effective boards through continuous learning and peer networking.”
“We are thrilled to welcome Beth to the ATEC Board,” said Pat Miles, chairman and CEO. “Her breadth of business, accounting and finance insight and her passion for life science technologies will be essential as ATEC continues its evolution into a dominant spine company. We would also like to thank Don, one of ATEC’s longest-standing Board members, for his guidance and support throughout our ongoing business transformation.”
“I am excited to be part of the world class team and Board of Directors at ATEC,” Altman told OTW. “As Chair of the Board’s Audit Committee, I intend to leverage my depth of life science accounting and finance experience to contribute to the sophistication of ATEC’s financial practices and reporting as the company evolves into a dominant spine company.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.